Wave Life Sciences Q2 net loss widens to $69.4 million; revenue falls to $2.3 million
Wave Life Sciences reported second-quarter 2026 results with revenue of $2.3 million, down from $8.7 million a year earlier, and a net loss of $69.4 million, up from $50.5 million. The company said cash, cash equivalents, and marketable securities were $490.6 million at June 30, 2026, with cash runway expected into the third quarter of 2028.
Key points
- Net loss per share was $0.34 in Q2 2026 versus $0.31 in Q2 2025.
- Research and development expenses rose to $51.3 million from $43.5 million; general and administrative expenses rose to $24.8 million from $18.0 million.
- Cash, cash equivalents, and marketable securities were $490.6 million at June 30, 2026, versus $602.1 million at December 31, 2025.
- An FDA meeting on a potential accelerated approval pathway for WVE-006 is scheduled for the end of summer 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.